Your monthly newsletter from the
"better way to get and use market intelligence" people |
|||||||||||||||
Table of Contents
|
|||||||||||||||
| 1) Increased risk with DES vs. BMS in Saphenous Vein Graphs (SVG)? Dr. Sanjay Kaul, FACC and director of the Vascular Physiology and Thrombosis Research Laboratory at Cedars-Sinai Medical Center (Los Angeles), and colleagues discussed the use of drug-eluting stents (DES) vs. bare metal stents (BMS) in the July 10, 2007 issue of the Journal of the American College of Cardiology. The authors noted a Dutch study which included 75 people who had previously received SVGs in 96 vessels. During the study, 38 patients received 60 sirolimus-eluting stents in 47 vessels, while 37 patients received 54 BMS in 49 vessels. Of the 38 patients who received a DES, 11 (29%) died over a 32-month follow-up period while no deaths were observed in the BMS group. Dr. Kaul noted that the results of the Dutch study are not surprising because the "FDA approved stents on the basis of a highly select patient population, which did not have the characteristics of the people in this particular trial." According to Dr. Kaul, it is not currently possible to definitively state why a DES might present a great hazard in a SVG. However, he noted that SVGs often have softer plaques and can accelerate the process of atherosclerosis. Dr. Kaul argued that that more studies of the safety of DES in SVG are needed. "Until a definitive study comes out which demonstrates that they are safe, I would stick with balloon angioplasty and bare-metal stents. They are not very effective, but they are safe," he said. Would you like to have summaries like this pushed to you as they occur via email or RSS? Is there another area of interest where you need current, timely clinical research or technology development information? Click here to learn more about our MIB Alerts - A Better Way...to stay up to date. Return to Top |
|||||||||||||||
| 2) Spectranetics TURBO-Booster FDA cleared to treat arterial occlusions in the leg Spectranetics announced July 2007 that it has received FDA clearance to market its TURBO-Booster product for the treatment of arterial stenoses and occlusions in the leg. This represents a broader indication for use compared to existing peripheral laser catheters. The TURBO-Booster functions as a guiding catheter facilitating directed ablation of blockages in the main arteries at or above the knee. The TURBO-Booster combined with Turbo elite laser catheters allows for removal of large amounts of plaque material within the SFA and popliteal arteries. The CELLO trial provided data to the FDA in support of the 510(k) for the TURBO-Booster. The study was a prospective registry with 61 patients in 16 centers within the US. Patients were included with stenoses and occlusions ≥ 70% and ≤ 100% of the vessel lumen in arteries from 4 to 7 mm in diameter. The reduction in % diameter stenosis was 35% following use of the TURBO-Booster with no major adverse events through 30 days. Keep tabs on your competition - get informed when key events like regulatory clearances happen. MIB Alerts provide regular updates on clinical research and technology development in your areas of interest. Click here to learn more about our MIB Alerts - A Better Way...to stay up to date. Return to Top |
|||||||||||||||
| 3) MedIntelliBase Custom Alerts - updated and more powerful MedIntelliBase Custom Alerts
A Better Way...to get and use medical industry market intelligence. Customizable Search - MIB Custom Alerts are tightly focused, completely customizable search agents powered by Human Intelligence™. Our industry experience and insight screen out what you don't want and deliver precisely the types of industry developments you do want. Precisely Targeted - MIB Custom Alerts precisely target your areas of interest by keeping you continuously updated on relevant market, clinical and technology developments. Pushed to You - MIB Custom Alerts are regularly pushed to you and your team via email or RSS feeds. Searchable Archives - Archives of your previous MIB Custom Alerts enable you to do quick retrospective searches to find the exact abstract or announcement you need within seconds. MIB Custom Alerts is part of MedIntelliBase Medical Industry Market Intelligence Tools: a set of vital tools for biotech and medical device executives enabling you to gain and sustain a competitive advantage.
For more information, click here or arrange to meet with us at the SIS 2007 conference in Seattle from August 1-3 by contacting us - See SIS 2007 below.
Return to Top |
|||||||||||||||
| 4) Science, Innovation, Synergy - SIS 2007 Conference in Seattle A Course in Cardiac, Vascular, and Neurovascular Therapeutics & Emerging Technology Symposium - August 1 - 4 Science, Innovation, Synergy is the premiere conference of its kind on the West Coast. A comprehensive course focusing on issues related to cardiac, vascular and neurovascular disease, SIS is unique in offering a forum for the specialties to interface. SIS provides physicians and healthcare professionals a state-of-the-art perspective of the field and a glimpse into the future technologies and treatments in cardiac, vascular and neurovascular intervention.
Return to Top |
|||||||||||||||
5) Link of the Month
|
|||||||||||||||
6) Fun Fact of the Month
|
|||||||||||||||
7) MedIntelliBase Custom Email Alerts...A Better Way  The information you need is just clicks away - click image above to see how.
MedIntelliBase Custom AlertsDoes this "quest for Market Intelligence" sound familiar?
 The information you need is just clicks away - click image above to see how.
MedIntelliBase Custom Alerts A Better Way...to get and use medical industry market intelligence.
MIB Alerts MedIntelliBase Custom Email Alerts are highly flexible, customized intelligent search filters powered by "Human Intelligence™" that give you convenient, timely, and tightly focused updates on new developments in your industry segment. MIB Alerts are especially suitable for busy Marketing, Business Development, and General Management executives in medical device and biotechnology companies.
A few examples of thousands of possibilities for Alert topics:You get much greater value from customizable MIB Alerts than from standard market reports and search engines. You choose the exact depth and breadth of intelligence required, realizing the greatest value for your market intelligence money. MedIntelliBase Market Intelligence Tools – MIB Alerts – MIB MarketTracks – MIB SMArtStats –
A Better Way…to get and use medical industry market intelligence.– MIB Market Research – MIB Customer Needs Analysis – Visit MedIntelliBase.com or contact us by clicking here. Return to Top |
|||||||||||||||
| 8) More Information Available at www.MedIntelliBase.com You can find more in-depth information about MedIntelliBase Custom Alerts - MIB MarketTracks - MIB SMArtStats - MIB MarketResearch - MIB Customer Needs Analysis. Visit the website at www.MedIntelliBase.com, request more information on the site, or Contact MedIntelliBase directly. MedIntelliBase Alerts will help you find the critical intelligence you need to make informed product development and business investment decisions. Return to Top |
|||||||||||||||
FYI:
Co-Editor: Vicky Hunsicker Sanko Phone - 425/869-8724 Assistant Editor & Market Research Analyst: Jordan Zornes Phone - 425/894-4147 www.MedIntelliBase.com Toll Free - 800/390-2756 Fax - 866/381-6119 ** The Next Phase Publishing; a division of Next Phase® Consultancy, Inc. © The Next Phase® Consultancy, Inc. 2007. All rights reserved. Return to Top |
